Chardan Capital reissued their buy rating on shares of iBio (NYSE:IBIO – Free Report) in a research report report published on Monday morning,Benzinga reports. They currently have a $5.00 target price on the stock.
Separately, StockNews.com upgraded iBio to a “sell” rating in a research note on Tuesday, March 18th.
View Our Latest Stock Report on iBio
iBio Price Performance
Institutional Trading of iBio
An institutional investor recently raised its position in iBio stock. Geode Capital Management LLC boosted its position in shares of iBio, Inc. (NYSE:IBIO – Free Report) by 52.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 83,797 shares of the company’s stock after acquiring an additional 28,775 shares during the period. Geode Capital Management LLC owned 0.85% of iBio worth $205,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 7.90% of the company’s stock.
About iBio
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Featured Articles
- Five stocks we like better than iBio
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Monster Beverage Stock: Short Report Risks vs Upside Potential
- How to Plot Fibonacci Price Inflection Levels
- Onsemi Stock Confirms Bottom, But What’s the Upside?
- How to Start Investing in Real Estate
- 3 Tech Leaders Announce Buybacks Totaling $85 Billion
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.